Baidu
map

血液检查可用于BRCA1,2突变携带者的检测

2013-05-20 MedSci MedSci原创

简单的血液检查将有助于诊断出携带有BRCA1和2突变的遗传性乳腺癌和卵巢癌。 巴勒斯坦耶路撒冷Hadassah 大学医院Sharett 肿瘤研究所住院部主任Asher Salmon博士报告称,对于疑似携带有BRCA1/2突变的女性,采用这种检查便可避免使用价格高昂的基因序列检测,也便于快速作出诊疗决策。这种检查只需6天就能获得结果,而目前采用的方法需要6周。 虽然这种新的血液检查仍处于

简单的血液检查将有助于诊断出携带有BRCA1和2突变的遗传性乳腺癌和卵巢癌。 巴勒斯坦耶路撒冷Hadassah 大学医院Sharett 肿瘤研究所住院部主任Asher Salmon博士报告称,对于疑似携带有BRCA1/2突变的女性,采用这种检查便可避免使用价格高昂的基因序列检测,也便于快速作出诊疗决策。这种检查只需6天就能获得结果,而目前采用的方法需要6周。 虽然这种新的血液检查仍处于早期研发阶段,但目前这方面的争议颇多。今年3月,美国某地方法院的法官驳回了犹他州盐湖城Myriad 基因公司和犹他大学提出的关于分离BRCA基因序列的专利申请。垄断了BRCA1/2检测市场的Myriad公司不服判决,正在提出上诉。 Salmon博士称,这项新的血液检查是Hadassah 大学专利保护研究项目的一部分。目前Salmon博士正在与Sharett研究所所长Tamar Peretz博士共同研发这项新的诊断技术。位于以色列Ramat Gan的一家生物技术公司Micromedic Technologies正试图将这项检查研制成一种风险评估工具,并且已经成立了一家名为Bio Gene 的子公司来推进这

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=36928, encodeId=1de2369284a, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150915/IMG55F7E62F9188B3419.jpg, createdBy=0a0a88658, createdName=lingshexiangya, createdTime=Tue Sep 15 17:33:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026213, encodeId=769a202621380, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Oct 14 01:25:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004896, encodeId=4cd42004896fc, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Nov 01 12:25:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423285, encodeId=d9c8142328570, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593971, encodeId=d50215939e10b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
    2015-09-15 lingshexiangya

    很棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=36928, encodeId=1de2369284a, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150915/IMG55F7E62F9188B3419.jpg, createdBy=0a0a88658, createdName=lingshexiangya, createdTime=Tue Sep 15 17:33:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026213, encodeId=769a202621380, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Oct 14 01:25:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004896, encodeId=4cd42004896fc, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Nov 01 12:25:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423285, encodeId=d9c8142328570, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593971, encodeId=d50215939e10b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=36928, encodeId=1de2369284a, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150915/IMG55F7E62F9188B3419.jpg, createdBy=0a0a88658, createdName=lingshexiangya, createdTime=Tue Sep 15 17:33:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026213, encodeId=769a202621380, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Oct 14 01:25:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004896, encodeId=4cd42004896fc, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Nov 01 12:25:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423285, encodeId=d9c8142328570, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593971, encodeId=d50215939e10b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
    2013-11-01 qblt
  4. [GetPortalCommentsPageByObjectIdResponse(id=36928, encodeId=1de2369284a, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150915/IMG55F7E62F9188B3419.jpg, createdBy=0a0a88658, createdName=lingshexiangya, createdTime=Tue Sep 15 17:33:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026213, encodeId=769a202621380, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Oct 14 01:25:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004896, encodeId=4cd42004896fc, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Nov 01 12:25:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423285, encodeId=d9c8142328570, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593971, encodeId=d50215939e10b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=36928, encodeId=1de2369284a, content=很棒, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150915/IMG55F7E62F9188B3419.jpg, createdBy=0a0a88658, createdName=lingshexiangya, createdTime=Tue Sep 15 17:33:00 CST 2015, time=2015-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2026213, encodeId=769a202621380, content=<a href='/topic/show?id=bcc68928808' target=_blank style='color:#2F92EE;'>#血液检查#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89288, encryptionId=bcc68928808, topicName=血液检查)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a6b240, createdName=俅侠, createdTime=Mon Oct 14 01:25:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2004896, encodeId=4cd42004896fc, content=<a href='/topic/show?id=2f48569264d' target=_blank style='color:#2F92EE;'>#携带者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56926, encryptionId=2f48569264d, topicName=携带者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=640c454, createdName=qblt, createdTime=Fri Nov 01 12:25:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423285, encodeId=d9c8142328570, content=<a href='/topic/show?id=504c368e51' target=_blank style='color:#2F92EE;'>#BRCA1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3687, encryptionId=504c368e51, topicName=BRCA1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a3d3767712, createdName=caobinglei8080, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593971, encodeId=d50215939e10b, content=<a href='/topic/show?id=63cc368459' target=_blank style='color:#2F92EE;'>#BRCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3684, encryptionId=63cc368459, topicName=BRCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=918e18200218, createdName=cmj14wellington, createdTime=Wed May 22 00:25:00 CST 2013, time=2013-05-22, status=1, ipAttribution=)]

相关资讯

预防性对侧乳腺切除无法降低乳腺癌复发风险

Dr. Sarah T. Hawley 密歇根大学肿瘤中心的研究者发现,尽管乳腺癌患者健侧乳腺继发癌症的风险很低,仍有大约70%的女性在确诊后选择双侧乳腺切除。 最近研究显示乳腺癌患者中,选择更积极的手术方式的人数增多。更多人选择对侧乳腺切除,这些患者是否存在过度治疗的问题?这项研究发现90%的接受双侧乳腺切除的女性过度担心肿瘤复发。但是对于大多数女性,一侧乳腺癌并不能增加对侧乳腺复发几率

J Pathol.:乳腺癌基因BRCA1有助治疗间皮瘤

恶性胸膜间皮瘤是肺和胸壁之间的癌症。它一般是由接触石棉引起,尽管罕见,全球的病例数却在不断增加,尽管有些病人对抗有丝分裂的化疗药物长春瑞滨(Vinorelbine)有响应,恶性胸膜间皮瘤的治疗方法依然相当有限。爱尔兰研究人员发现乳腺癌基因BRCA1的变化与恶性胸膜间皮瘤有关。 这项研究的成果发表在《病理学期刊》上,研究人员观察了144例间皮瘤样本,发现近40%没有表达BRCA1蛋白,这与对长

美最高法院要求重审乳腺癌基因专利案

       美国最高法院3月26日做出裁决,要求联邦巡回上诉法院重新审理涉及万基遗传科技公司的乳腺癌基因专利案。           联邦巡回上诉法院专门负责审理专利案件。该院去年7月曾裁定,万基公司可以拥有针对乳腺癌测试基因BRCA1和BRCA2的专利。

Cancer Res.:BRCA1基因突变乳腺癌中的RB1基因异常

6月15日,Cancer Research杂志在线报道了BRCA1基因突变携带者的乳腺癌研究的最新进展。生殖细胞系BRCA1基因突变携带者的乳腺癌常显示基底样分子亚型的典型特征。然而,BRCA1功能失调导致哪些基因反复突变尚不清楚。 在这项研究中,研究者利用基因表达谱对577例乳腺肿瘤进行分子亚型分类,其中包括72例乳腺肿瘤BRCA1/2突变基因携带者。以RB1位点为重点,研究者使用覆盖RB1基

Baidu
map
Baidu
map
Baidu
map